GR-1405

N/A

Report date: 2022/10/17 18:34:02

Base Information

Drug NameGR-1405
Drug Alias NameGR-1405
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionProgrammed death-ligand 1 blockers
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsSolid tumoursHead and Neck NeoplasmsTriple Negative Breast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesGenrix (Shanghai) Biopharmaceutical Co LtdChongqing Genrix Biopharmaceutical Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesChongqing Genrix Biopharmaceutical Co LtdGenrix (Shanghai) Biopharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursHead and Neck NeoplasmsTriple Negative Breast Neoplasms +[5] 

Other Information

ATC CodeN/A
Related LinksN/A